Clinuvel制药公司获得欧盟药监局关于关键白癜风三期研究的最终科学建议

美股速递
Apr 24

Clinuvel Pharmaceuticals Ltd宣布,已成功获得欧洲药品管理局(EMA)针对其关键性白癜风三期临床试验的最终科学建议。这一重要进展标志着该公司在白癜风治疗领域的研发项目迈入新的阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10